Hormone Protect by Xymogen
Hormone Protect by Xymogen is a supplement designed to safeguard estrogen-sensitive tissues.* This hormone product may not only support estrogen metabolism but also aid in the detoxification and neutralization of harmful estrogen metabolites.* Hence, it is a popular choice among healthcare practitioners.*
Who Should Consider Hormone Protect by Xymogen?
Hormone Protect by Xymogen may support your health if you:
- are a woman experiencing hormonal imbalances,*
- are undergoing menopause,*
- want to support estrogen metabolism and cellular health*
How May Hormone Protect by Xymogen Affect Your Health?
Xymogen Hormone Protect may have several health benefits, namely:
- supporting healthy estrogen metabolism,*
- promoting detoxification of estrogen metabolites,*
- aiding cellular health in tissues that are estrogen-sensitive,*
- backing up anti-oxidant activity*
Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about this product.
Recommendation:
Xymogen suggests taking one to two Hormone Protect capsules daily, or as directed by your healthcare practitioner.
Consult your healthcare practitioner prior to use. Individuals taking medication or receiving cancer treatment should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.
Serving Size: 2 Capsules
Servings Per Container: 30 or 60
Amount Per Serving: |
DIM (diindolylmethane) 300 mg
Glucoraphanin (from broccoli extract)(Brassica oleracea italica)(seed)(TrueBroc®) 60 mg
Other Ingredients: HPMC (capsule), stearic acid, magnesium stearate, silica, and microcrystalline cellulose.
Does Not Contain: Wheat, gluten, yeast, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.
Storage: Keep tightly closed in a cool, dry place out of reach of children.
Trademarks: Produced under US patent 5,725,895; 5,968,505; 5,968,567; 6,177,122; and 6,242,018 licensed from Brassica Protection Products LLC; truebroc is a trademark of Brassica Protection Products LLC.
* The statements have not been evaluated by the Food and Drug Administration.
Products listed are not intended to diagnose, treat, cure, or prevent disease.
© 2012 2014 XYMOGEN®
Click here to view Data Sheet
LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518
References:
- Herrmann S, Seidelin M, Bisgaard HC, et al. Indolo[3,2-b]carbazole inhibits gap junctional intercellular communication in rat primary hepatocytes and acts as a potential tumor promoter. Carcinogenesis. 2002 Nov;23(11):1861-68. [PMID: 12419834]
- Rajoria S, Suriano R, Parmar PS, et al. 3,3’-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011 Mar;21(3):299-304. [PMID: 21254914]
- Sepkovic DW, Stein J, Carlisle AD, et al. Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2957-64. [PMID: 19861518]
- Dalessandri KM, Firestone GL, Fitch MD, et al. Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-67. [PMID: 15623462]
- Del Priore G, Gudipudi DK, Montemarano N, et al. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol. 2010 Mar;116(3):464-67. [PMID: 19939441]
- Fares F, Azzam N, Appel B, et al. The potential efficacy of 3,3’-diindolylmethane in prevention of prostate cancer development. Eur J Cancer Prev. 2010 May;19(3):199-203. [PMID: 20010430]
- Keum YS. Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann N Y Acad Sci. 2011 Jul;1229:184-89. [PMID: 21793854]
- Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol. 2008 Jan;21(1):93-101. [PMID: 18052105]
- Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006 Aug;1766(1):63-78. [PMID: 16675129]
- Cornblatt BS, Ye L, Dinkova-Kostova AT, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007 Jul;28(7):1485-90. [PMID: 17347138]
- Misiewicz I, Skupińska K, Kowalska E, et al. Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NAD(P)H:quinone reductase and apoptosis in human lymphoblastoid cells. Acta Biochim Pol. 2004;51(3):711-21. [PMID: 15448733]
- Myzak MC, Dashwood RH. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett. 2006 Feb 28;233(2):208-18. [PMID: 16520150]
1 Review Hide Reviews Show Reviews
-
Mrs.
Got this because it''s what my Dr suggested. So glad I found Covenant, great customer service.